Saudi Arabia Sfda Medical Device Registration Consultant
An SFDA medical device registration consultant should resolve the regulatory decisions before an application is prepared: is the proposed product a medical device or IVD, which Saudi risk rules apply, who can represent the manufacturer, and which existing evidence actually covers the Saudi configurations?
Saudi Arabia generally requires SFDA registration and Medical Device Marketing Authorization (MDMA) before a medical device is placed on its market. Article 8 of the implementing regulation provides limited, conditional non-commercial exceptions; a research label or a foreign approval does not by itself establish an exemption.
Determine the regulatory perimeter before choosing a submission route
Start with the manufacturer’s actual intended purpose, the wording of claims and instructions, the intended user, the mechanism of action and the complete product configuration. SFDA definitions cover software, IVDs and accessories as well as physical instruments. Borderline products and mixed-function systems need a documented regulatory rationale, not a decision based on a distributor’s tariff code.
| Product fact pattern | Strategy question | Safe next step |
|---|---|---|
| Software predicts or monitors a disease | Is it software with an intended medical purpose? | Compare the intended-purpose statement and functions against the device definition; document classification before commercial claims. |
| Reagent or analyzer examines human specimens | Is it an IVD and which IVD risk rule applies? | Prepare the analyte, specimen, target condition, user and result-use profile; assess the IVD rules separately. |
| Accessory supplied with a main device | Is the item an accessory and how does it affect the covered configuration? | Map accessory purpose, combinations, labels and device/model groupings; justify the rule for each relevant item. |
| Device presented as a research or exhibition sample | Is a specific non-commercial Article 8 exception available? | Check the precise purpose and SFDA import-permit requirements; do not infer permission for routine sale. |
| Product also involves chemicals, pharmaceuticals or non-device functions | Which SFDA regulatory regime governs each component? | Escalate a classification conflict; do not select SABER or an MDMA dossier by assumption. |
Fix the risk classification and identify the facts that can change it
The manufacturer bears responsibility for SFDA device classification, must consider applicable rules and justify the highest applicable risk classification, including relevant accessories. IVDs have their own A–D risk framework. A prior EU or US class is useful background, not a substitute for applying the Saudi rules.
For a commercially supplied IVD, use the IVD-specific classification rules in Annex 5 of MDS-REQ 1. MDS-G022 concerns in-house IVDs developed and used within healthcare facilities; it is not the standard market-entry route for commercially supplied IVDs.
A consultant’s written classification memo should record at least:
- The exact medical claims, indications, contraindications, patient group and professional or lay user;
- Duration and invasiveness, contact with the body, energy source, software decisions and any measuring or sterile features;
- For IVDs: analyte, specimen, result interpretation, screening versus monitoring purpose and public-health consequences;
- A rule-by-rule rationale, the highest applicable class, disputed assumptions and information still requested from the manufacturer.
Separate the consultant, manufacturer, authorized representative and importer
An advisory consultant does not automatically become the legal Authorized Representative (AR) or the importer. Under the implementing regulation, an AR is a Saudi-based legal person authorized in writing by a foreign manufacturer; MDS-REQ 9 requires AR licensing and documented manufacturer agreements. The licensing rules also separately cover establishments providing medical-device technical consultation in Saudi Arabia. Verify the actual licensed activity and contractual scope of each engaged entity. The title “consultant” does not establish the licensing position of an adviser working outside Saudi Arabia; assess the actual services, place of activity and contracting entity rather than assuming either a licence requirement or an exemption.
MDS-REQ 1 allows an overseas manufacturer to submit an MDMA application itself or to use its Saudi authorized representative, subject to the applicable requirements. Do not assume an AR is the only possible applicant: identify the actual applicant and verify the licences and agreements required for the selected arrangement.
| Actor | Decision or obligation | Pre-filing verification |
|---|---|---|
| Manufacturer | Owns intended purpose, device classification and supporting technical evidence. | Confirm legal manufacturer, sites, versions and sign-off owner. |
| Saudi Authorized Representative | Carries authorized SFDA-facing responsibilities for the foreign manufacturer. | Check AR licence, manufacturer coverage, product group and agreement; resolve overlapping appointments. |
| Importer/distributor | Performs supply-chain activities subject to its applicable SFDA licensing and controls. | Check who imports, stores and distributes; do not treat AR appointment as import approval. |
| Regulatory consultant | Advises on scope, readiness, gap priorities and route; may hold another role only if separately established. | Define deliverables, access to evidence and responsibility for regulator communications. |
Build a gap register that changes a filing decision
A useful readiness assessment does not count uploaded PDFs. It tests whether each claim, design variant and Saudi model is traceable to current supporting records. Classify each gap as blocking (cannot justify the route or safety/performance), conditional (clarification or localized adaptation), or maintenance (post-approval control). The following is an advisory prioritization tool, not an SFDA-issued checklist.
| Gap discovered | Evidence to inspect | Decision before spending on testing or filing |
|---|---|---|
| Claims or model mismatch | Intended use, IFU, labels, variant/model list | Freeze the Saudi scope; reconcile inconsistent indications before choosing class or grouping. |
| Insufficient safety/performance support | Risk file, design verification/validation, clinical or IVD performance data | Map each claimed function to evidence; define only targeted additional work. |
| Unclear manufacturer or QMS perimeter | Legal-manufacturer details, manufacturing sites, relevant QMS evidence | Resolve responsible entity and coverage of activities/sites before dossier reuse. |
| Local responsibility unresolved | AR appointment, licence scope, supply-chain map | Confirm which licensed entity performs which activity and who receives SFDA queries. |
| Old dossier or upcoming design change | Dossier revision register, software versions, change-control assessment | Decide whether the evidence describes the Saudi launch version; assess significant-change implications. |
Reuse foreign evidence only after testing its fit
Existing EU, US or other-market files can reduce duplication where they contain relevant and current evidence, but foreign clearance is not itself Saudi MDMA. Compare the intended use, model identifiers, manufacturing sites, standards and test configurations against the exact proposed Saudi scope. A different population, language, performance claim or software release can break the evidence chain.
- Reuse without new work only where the document version, model, claim and evaluated configuration match;
- Adapt where substance is adequate but Saudi presentation, scope or identification needs reconciliation;
- Commission further assessment or testing only after defining the unresolved safety/performance proposition;
- Do not promise “approval by equivalence” or automatic recognition of CE marking or FDA clearance.
Use decision gates instead of beginning with portal entry
- Gate 1 — confirm device/IVD status and resolve any boundary with another regulatory regime.
- Gate 2 — lock the intended purpose, Saudi model list, accessories and justified risk class.
- Gate 3 — confirm legal manufacturer, appropriately licensed Saudi roles and representation terms.
- Gate 4 — close material technical-evidence gaps; identify localization and applicable surveillance/change obligations.
- Gate 5 — issue a go/no-go memo for submission. Only then commission the detailed MDMA filing and response workflow.
If the product is undergoing material redesign, revisit Gates 1–4 rather than filing against obsolete specifications. SFDA guidance MDS-G012 distinguishes significant and non-significant changes after MDMA, and significant changes can require SFDA approval before supplying the affected device.
Exceptions and portfolio changes: test the specific conditions
Article 8 lists conditional grounds for certain non-commercial uses, including research, educational, individual-use, custom-made and exhibition scenarios, with import-permit rules. These do not create a general commercial marketing exemption. For an IVD, use the separate IVD classification analysis; for a multiproduct portfolio, do not assume that one class, AR agreement or evidence file covers every device and group. Regulatory strategy should therefore specify exclusions and unresolved boundary questions in writing.
Deliverables to demand from an SFDA pre-filing consultant
Ask for a signed decision memo rather than a generic “registration package”: product-scope map, classification rationale, AR/importer role map, evidence gap register with priority and owner, evidence-reuse assessment, exceptions analysis and a go/no-go recommendation. The SFDA alone decides applications; no consultant can guarantee authorization or a fixed review date.
After the route is settled, the detailed work belongs on the appropriate service pages:
Official sources
Read the current SFDA instruments and check for updates before filing; law and implementing regulation take precedence over editorial strategy.
Saudi SFDA questions that can change the registration strategy
Can our CE certificate or US FDA clearance replace Saudi MDMA?
Do not assume so. Foreign evidence may support the Saudi technical file, but the Saudi product scope and SFDA authorization requirements still need their own assessment.
Can a distributor or an independent adviser act as our Saudi AR?
Only if the proposed entity meets the applicable legal, licensing and authorization conditions. Review its SFDA-licensed activity, manufacturer-specific AR coverage and written agreement; distribution or consultancy alone does not prove AR status.
Is a low-risk or research-only device automatically exempt?
No. Risk class does not establish a general commercial exemption. Conditional non-commercial exceptions under Article 8 must be assessed against the intended use and applicable SFDA permit conditions.
What if our IVD has a class assigned in Europe?
Reassess it under the SFDA IVD A–D rules using the analyte, specimen, clinical purpose and public-health impact. An EU IVDR class is not the Saudi classification decision.
Should we pay for new laboratory tests before a gap review?
Usually decide that after mapping existing reports to the Saudi models, claims and applicable evidence requirements. A targeted gap statement prevents unnecessary retesting while exposing genuine safety/performance omissions.